Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes

Virology
Stephan MaerschL Perabo

Abstract

Therapeutic gene transfer by adeno-associated virus of serotype 2 (AAV-2) vectors is hampered in patients with pre-existing immunity. Molecular engineering was recently used to identify key immunogenic amino acid residues of the viral capsid and generate mutants with decreased antibody recognition. Here we explored the importance of finely tuning amino acid identity at immunogenic sites to optimize vector phenotype. A capsid library was generated by codon randomization at five positions where substitutions were shown to yield antibody evading phenotypes. Screening this library to isolate immune-escaping mutants allowed an exhaustive scan of combinations of the 20 natural amino acids at each position and yielded variants that remained infectious when incubated with serum or IVIG concentrations that completely neutralize AAV-2. Clones obtained replacing different residues at the same positions displayed strikingly different phenotypes, demonstrating that a precise choice of amino acid substitutions is fundamental to optimize immune-escaping, packaging ability, infectivity and tropism.

References

Mar 1, 1997·Nature Medicine·K J FisherJ M Wilson
Sep 22, 1999·Gene Therapy·N ChirmuleJ Wilson
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·W XiaoJ M Wilson
Jul 24, 2002·Proceedings of the National Academy of Sciences of the United States of America·Qing XieMichael S Chapman
Jul 5, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Luca PeraboMichael Hallek
Sep 27, 2003·Journal of Virology·A KernJ A Kleinschmidt
Nov 15, 2005·The Journal of Gene Medicine·Luca PeraboHildegard Büning
Jan 24, 2006·Nature Biotechnology·Narendra MaheshriDavid V Schaffer
Jul 11, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhijian WuR Jude Samulski
Apr 18, 2008·Gene Therapy·C Mueller, T R Flotte
May 3, 2008·The Journal of Gene Medicine·Hildegard BüningMichael Hallek
May 27, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Wuping LiRichard J Samulski
Aug 30, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·James T KoerberDavid V Schaffer
Jan 13, 2009·The Journal of Infectious Diseases·Roberto CalcedoJames M Wilson

❮ Previous
Next ❯

Citations

Jul 25, 2012·Therapeutic Delivery·Ulrich Hacker, Hildegard Büning
Feb 28, 2013·Human Gene Therapy Methods·Vedell Louis JeuneThomas Weber
Oct 30, 2013·Human Gene Therapy·Aravind Asokan, R Jude Samulski
Jan 26, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Aravind AsokanR Jude Samulski
Jan 6, 2011·Expert Opinion on Biological Therapy·Luc J W van der LaanQiuwei Pan
Sep 22, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Dirk Grimm, Sergei Zolotukhin
Aug 25, 2015·Current Opinion in Pharmacology·Hildegard BüningUlrich Hacker
Sep 4, 2015·Journal of Structural Biology·Sujata HalderMavis Agbandje-McKenna
Jun 5, 2015·PloS One·Timo SieberMartin Trepel
Jul 28, 2016·Current Opinion in Virology·Dongsheng Duan
Feb 5, 2015·Revista da Associação Médica Brasileira·José Ednésio da Cruz FreireLéa Maria Bezerra de Menezes
Sep 25, 2017·Biotechnology and Bioengineering·David Sharon, Amine Kamen
May 23, 2019·Human Genetics·Minyoung Lee, Hyongbum Kim
Sep 12, 2013·Reviews in Medical Virology·Sangeetha HareendranGiridhara R Jayandharan
Aug 5, 2017·Frontiers in Pharmacology·Ruchita SelotGiridhara R Jayandharan
Jul 3, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michael F NasoWilliam R Strohl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.